Andrej Besse
Medizinische Onkologie und Hämatologie · Dept. I
HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
Besse A, Sedlarikova L, Büchler L, Kraus M, Yang C, Strakova N, Soucek K, Navratil J, Svoboda M, Welm A, Jörger M, Driessen C, Besse L. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. Br J Cancer 2024
Jul 5, 2024HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
Jul 5, 2024Br J Cancer 2024
Besse Andrej, Sedlarikova Lenka, Büchler Lorina, Kraus Marianne, Yang Chieh-Hsiang, Strakova Nicol, Soucek Karel, Navratil Jiri, Svoboda Marek, Welm Alana L, Jörger Markus, Driessen Christoph, Besse Lenka
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L, Kraus M, Besse A, Driessen C, Tarantino I. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma. Sci Rep 2023; 13:4411.
Mar 17, 2023The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Mar 17, 2023Sci Rep 2023; 13:4411
Besse Lenka, Kraus Marianne, Besse Andrej, Driessen Christoph, Tarantino Ignazio
Mutant driving the Warburg Effect in Mantle Cell lymphoma.
Kliebhan J, Besse A, Kampa-Schittenhelm K, Schittenhelm M, Driessen C. Mutant driving the Warburg Effect in Mantle Cell lymphoma. Clin Case Rep 2022; 10:e6296.
Oct 3, 2022Mutant driving the Warburg Effect in Mantle Cell lymphoma.
Oct 3, 2022Clin Case Rep 2022; 10:e6296
Kliebhan Johannes, Besse Andrej, Kampa-Schittenhelm Kerstin, Schittenhelm Marcus, Driessen Christoph
Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
Schwestermann J, Besse A, Driessen C, Besse L. Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. Front Oncol 2022; 12:899272.
May 26, 2022Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors.
May 26, 2022Front Oncol 2022; 12:899272
Schwestermann Jonas, Besse Andrej, Driessen Christoph, Besse Lenka
Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Bolomsky A, Caers J, Hübl W, Schreder M, Zojer N, Driessen C, Tang J, Besse L, Heckman C, Kubicek S, Hannich J, Miettinen J, Malyutina A, Besse A, Huber J, Fellinger S, Breid H, Parsons A, Klavins K, Ludwig H. Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Adv 2021; 5:4125-4139.
Oct 26, 2021Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
Oct 26, 2021Blood Adv 2021; 5:4125-4139
Bolomsky Arnold, Caers Jo, Hübl Wolfgang, Schreder Martin, Zojer Niklas, Driessen Christoph, Tang Jing, Besse Lenka, Heckman Caroline A, Kubicek Stefan, Hannich J Thomas, Miettinen Juho J, Malyutina Alina, Besse Andrej, Huber Julia, Fellinger Stefanie, Breid Helene, Parsons Alun, Klavins Kristaps, Ludwig Heinz
High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
Besse L, Besse A, Kraus M, Maurits E, Overkleeft H, Bornhauser B, Bourquin J, Driessen C. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. Cells 2021; 10
Oct 22, 2021High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors
Oct 22, 2021Cells 2021; 10
Besse Lenka, Besse Andrej, Kraus Marianne, Maurits Elmer, Overkleeft Herman S, Bornhauser Beat, Bourquin Jean-Pierre, Driessen Christoph
Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment
Ring S, Spiegl M, Besse A, Bonilla W, Stemeseder F, Schmidt S, Orlinger K, Krebs P, Ludewig B, Wenger R, Hartmann F, Cupovic J, Onder L, Lütge M, Pérez Shibayama C, Gil Cruz C, Scandella E, De Martin A, Mörbe U, Flatz L. Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment. Nat Commun 2021; 12:4734.
Aug 5, 2021Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment
Aug 5, 2021Nat Commun 2021; 12:4734
Ring Sandra, Spiegl Matthias, Besse Andrej, Bonilla Weldy V, Stemeseder Felix, Schmidt Sarah, Orlinger Klaus K, Krebs Philippe, Ludewig Burkhard, Wenger Robert, Hartmann Fabienne, Cupovic Jovana, Onder Lucas, Lütge Mechthild, Pérez Shibayama Christian Ivan, Gil Cruz Cristina, Scandella Elke, De Martin Angelina, Mörbe Urs, Flatz Lukas
Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Besse L, Pilon M, Farhan H, Vulpe C, Overkleeft H, Driessen C, Ståhlman M, Huber J, Bolomsky A, Ludwig H, Hannich J, Loguinov A, Everts B, Berkers C, Besse A, Borén J, Florea B, Sathianathan M, Stolze S, Sobh A, Zaal E, van der Ham A, Ruiz M, Phuyal S, Büchler L. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. Cancer Res 2021; 81:4581-4593.
Jun 22, 2021Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma
Jun 22, 2021Cancer Res 2021; 81:4581-4593
Besse Lenka, Pilon Marc, Farhan Hesso, Vulpe Christopher D, Overkleeft Herman S, Driessen Christoph, Ståhlman Marcus, Huber Julia, Bolomsky Arnold, Ludwig Heinz, Hannich J Thomas, Loguinov Alex, Everts Bart, Berkers Celia R, Besse Andrej, Borén Jan, Florea Bogdan I, Sathianathan Marc, Stolze Sara C, Sobh Amin, Zaal Esther A, van der Ham Alwin J, Ruiz Mario, Phuyal Santosh, Büchler Lorina
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
Byrgazov K, Besse A, Kraus M, Slipicevic A, Lehmann F, Driessen C, Besse L. Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. Hemasphere 2021; 5:e602.
Jun 12, 2021Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
Jun 12, 2021Hemasphere 2021; 5:e602
Byrgazov Konstantin, Besse Andrej, Kraus Marianne, Slipicevic Ana, Lehmann Fredrik, Driessen Christoph, Besse Lenka
Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Byrgazov K, Kraus M, Besse A, Slipicevic A, Lehmann F, Driessen C, Besse L. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. Leuk Res 2020; 101:106499.
Dec 31, 2020Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs
Dec 31, 2020Leuk Res 2020; 101:106499
Byrgazov Konstantin, Kraus Marianne, Besse Andrej, Slipicevic Ana, Lehmann Fredrik, Driessen Christoph, Besse Lenka
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
Sep 20, 2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Sep 20, 2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo
Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Barrio S, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou R, Braggio E, Stewart A, Raab M, Einsele H, Driessen C, Chatterjee M, Leich E, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Kortüm K. Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 2018
Jul 19, 2018Spectrum and functional validation of PSMB5 mutations in multiple myeloma
Jul 19, 2018Leukemia 2018
Barrio Santiago, Martinez-Lopez Joaquin, Rosenwald Andreas, Beckmann Roland, Bargou Ralf C, Braggio Esteban, Stewart A Keith, Raab Marc S, Einsele Hermann, Driessen Christoph, Chatterjee Manik, Leich Ellen, Stühmer Thorsten, Da-Viá Matteo, Barrio-Garcia Clara, Lehners Nicola, Besse Andrej, Cuenca Isabel, Garitano-Trojaola Andoni, Fink Severin, Kortüm K Martin
The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
Krupkova O, Cambria E, Besse L, Besse A, Bowles R, Wuertz-Kozak K. The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies. JOR Spine 2018; 1:e1003.
Mar 15, 2018The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies.
Mar 15, 2018JOR Spine 2018; 1:e1003
Krupkova Olga, Cambria Elena, Besse Lenka, Besse Andrej, Bowles Robert, Wuertz-Kozak Karin
Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. BJU Int 2017
Nov 21, 2017Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir
Nov 21, 2017BJU Int 2017
Abt Dominik, Driessen Christoph, Engeler Daniel, Schmid Hans-Peter, Slaby Ondrej, Vodinska Martina, Silzle Tobias, Bader Juergen, Kraus Marianne, Sedlarikova Lenka, Besse Andrej, Besse Lenka
The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017; 7:e589.
Jul 28, 2017The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways
Jul 28, 2017Blood Cancer J 2017; 7:e589
Besse Lenka, Kraus Marianne, Besse Andrej, Bader J, Silzle Tobias, Mehrling T, Driessen Christoph
Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
Besse A, Besse L, Overkleeft H, Bader J, Kraus M, Morgan G, Weinhold N, Rasche L, Stolze S, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia 2017; 32:391-401.
Jul 5, 2017Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma
Jul 5, 2017Leukemia 2017; 32:391-401
Besse Andrej, Besse Lenka, Overkleeft H S, Bader J, Kraus Marianne, Morgan G J, Weinhold N, Rasche L, Stolze S C, Driessen Christoph
Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes
Xin B, Groll M, Driessen C, van der Stelt M, Kisselev A, van der Marel G, Filippov D, Florea B, Besse A, Huber E, de Bruin G, Overkleeft H. Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes. J Med Chem 2016; 59:7177-87.
Aug 1, 2016Structure-Based Design of β5c Selective Inhibitors of Human Constitutive Proteasomes
Aug 1, 2016J Med Chem 2016; 59:7177-87
Xin Bo-Tao, Groll Michael, Driessen Christoph, van der Stelt Mario, Kisselev Alexei F, van der Marel Gijsbert A, Filippov Dmitri V, Florea Bogdan I, Besse Andrej, Huber Eva M, de Bruin Gerjan, Overkleeft Herman S